Back to search

Belgium· BE-AMP-SAM474622-00

Kineret 100 mg/0.67 ml

A anakinra product containing anakinra, registered in Belgium by Swedish Orphan Biovitrum (Publ). The same ATC class is registered in 13 of our 19 countries.

ATC L04AC03

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedKineret 100 mg/0.67 mlATCL04AC03REGISTER NO.BE-AMP-SAM474622-00PACKS LISTED2CHECKEDSeptember 26, 2026

Where it is registered

Anakinra is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AC03 (anakinra), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose

Anakinra · ATC L04AC03

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Anakinra
Manufacturer
Swedish Orphan Biovitrum (Publ)
Country
Belgium (BE)
ATC code
L04AC03
ATC class
Anakinra
Defined daily dose
0.1 g, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    3225281
  • be_apb
    7720287

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

375 interactions on record for anakinra.

Graded by severity as the source publishes them — 31 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Anakinra · interactions on record

375 records

  • 31 severe
  • 337 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • PrednisoloneA07EA01moderate
  • HydrocortisoneA07EA02moderate
  • PrednisoneA07EA03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/1ff3e813-b5ac-4a10-98f6-952d0455404e
GET /v1/drugs/1ff3e813-b5ac-4a10-98f6-952d0455404e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Kineret 100 mg/0.67 ml",
  "name_fr": "Kineret 100 mg/0.67 ml",
  "name_nl": "Kineret 100 mg/0.67 ml",
  "amp_code": "SAM474622-00",
  "strengths": [
    "150.0000"
  ],
  "pack_count": 3,
  "substances": [
    "Anakinra",
    "Disodium Edetate Dihydrate",
    "Sodium Chloride",
    "Sodium Hydroxide",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Anakinra",
  "authorisation_numbers": [
    "EU/1/02/203/005",
    "EU/1/02/203/006",
    "EU/1/02/203/007"
  ]
}

See everything about anakinra.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.